Skip to main
TDOC

Teladoc (TDOC) Stock Forecast & Price Target

Teladoc (TDOC) Analyst Ratings

Based on 17 analyst ratings
Hold
Strong Buy 18%
Buy 12%
Hold 71%
Sell 0%
Strong Sell 0%

Bulls say

Teladoc Health is facing some challenges from competitors in various markets, which could potentially impact their economic returns and require increased sales and marketing expenses to maintain their market leader position. However, the company has a strong advantage in its operating efficiency and ability to launch new services, which could continue to drive growth. Management's focus on expanding virtual care and increasing adoption rates will be crucial for the company's long-term success, and if they can successfully adapt their value propositions, it could lead to upward pressure on their stock's valuation.

Bears say

Teladoc Health is facing challenges in its BetterHelp segment, with slower growth and a reduction in membership causing uncertainty about the path forward. However, the company's push towards whole-person health through its Primary 360 platform and its market leader position give it potential for long-term growth and a competitive advantage. The shift towards insurance revenue at BetterHelp could present a downside risk to the segment's profitability in the short term, but cost-cutting measures could help offset this impact.

Teladoc (TDOC) has been analyzed by 17 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 12% recommend Buy, 71% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Teladoc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Teladoc (TDOC) Forecast

Analysts have given Teladoc (TDOC) a Hold based on their latest research and market trends.

According to 17 analysts, Teladoc (TDOC) has a Hold consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Teladoc (TDOC)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.